Navigation Links
Pacira Pharmaceuticals, Inc. Reports First Quarter 2011 Financial Results
Date:5/11/2011

nd, parallel group, placebo-controlled bunionectomy trial was presented at the 2011 American Academy of Orthopaedic Surgeons Annual Meeting and the Orthopaedic Research Society's 57th Annual Meeting. The data demonstrated that the median time to first use of opioid rescue medication was 7.2 hours for patients treated with EXPAREL compared with 4.3 hours for patients on placebo (p<0.0001) and that patients treated with EXPAREL had comparable safety in wound healing and significantly improved efficacy in pain reduction compared to patients treated with placebo.  
  • Completed an IPO:  On February 8, 2011, Pacira sold an aggregate of 6 million shares of its common stock at $7.00 per share resulting in 2011 net proceeds of approximately $37 million.
  • Presented new Phase 1 study data on subjects with hepatic impairment: In March 2011, data from Pacira's Phase 1 study evaluating EXPAREL in subjects with moderate, stable hepatic impairment was presented at the 2011 American Society for Clinical Pharmacology and Therapeutics 112th Annual Meeting. Results from the Phase 1 open-label, parallel group volunteer study demonstrated that the differences in plasma exposure of EXPAREL between subjects with moderate, stable hepatic impairment compared to subjects with normal hepatic function were small and unlikely to require a dose adjustment of EXPAREL.
  • Presented new preclinical study data on the administration of EXPAREL via peripheral nerve block and on the compatibility of EXPAREL with Lidocaine: In April 2011, new data from two preclinical studies were presented at the Experimental Biology 2011 Annual Meeting. Results from the two preclinical studies demonstrated that EXPAREL was safe when administered in animals as peripheral nerve block and that EXPAREL may be locally administered after waiting 20 minutes following local administration of lidocaine, without potential for an interaction. Additional studies are underway to
    '/>"/>

  • SOURCE Pacira Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Pacira Pharmaceuticals, Inc. Announces EXPAREL™ Data Presentations
    2. Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2011 Financial Results Webcast and Conference Call
    3. Pacira Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
    4. Pacira Pharmaceuticals Reports Fourth Quarter and 2010 Financial Results
    5. Pacira Pharmaceuticals to Present at the Barclays Capital 2011 Global Healthcare Conference
    6. Pacira Pharmaceuticals EXPAREL™ Data to be Featured at 2011 ASCPT 112th Annual Meeting
    7. Pacira Pharmaceuticals Highlights Additional Safety Data on EXPAREL™ for Postsurgical Pain Relief at 2011 American Academy of Orthopaedic Surgeons Annual Meeting
    8. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
    9. Pacira Pharmaceuticals Presents New Data from EXPAREL Phase 3 Study at Orthopaedic Research Societys 57th Annual Meeting
    10. Pacira Pharmaceuticals Announces FDA Acceptance of EXPAREL™ New Drug Application for Pain Management
    11. Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/6/2015)... 2015   Cepheid (Nasdaq: CPHD ) today ... 2015 second quarter ended June 30, 2015 on Thursday, ... The Company will host a management presentation ... 2015, to discuss the results.  To access the live ... at least 15 minutes before the scheduled start time ...
    (Date:7/6/2015)... China Information Technology, Inc. (the "Company" or ... cloud-based platform, exchange, and big data solutions in ... launched its mobile app for Healthcare One Pass, ushering ... mobile devices. The Company jointly hosted the launch ceremony ... and Shenzhen News Net.   The mobile app ...
    (Date:7/4/2015)... , Spanje, July 4, 2015 /PRNewswire/ ... Y-90 harsmicrosferen aan eerstelijns chemotherapie voor patiënten ... lever (mCRC) verlengt de progressievrije overleving in ... niet-resectabele, gemetastaseerde colorectale kanker (mCRC) die alleen ... verbetering gezien in progressievrije overleving (PFS) in ...
    Breaking Medicine Technology:CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 2Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 3Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 4Nieuwe SIRFLOX onderzoeksgegevens gepresenteerd op World Congress of Gastrointestinal Cancer 5
    ... EDISON, N.J., Dec. 7 Q-Med AB and Oceana Therapeutics, Inc. ... primary endpoints for the treatment of fecal incontinence. , Q-Med AB ... the FDA during the first quarter of 2010 based on the ... result of years of hard work as we developed a product ...
    ... , SAN DIEGO, Dec. 7 CareFusion (NYSE: ... six new Pyxis® medication management products at the 44th American ... Exhibition Dec. 6 -10 in Las Vegas. , CareFusion is ... Pyxis products rank number one in user satisfaction ratings by ...
    Cached Medicine Technology:Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 2CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition 3
    (Date:7/7/2015)... ... July 07, 2015 , ... ... patient advocate, will be recognized by the White House as a “Champion of ... newly-launched President’s Precision Medicine Initiative, the Champions of Change program recognizes Gleason and ...
    (Date:7/6/2015)... London, UK (PRWEB) , ... July 07, 2015 ... ... segments in the in vitro universe. Increasing incidence of AIDS, advances in the ... the key growth driving forces. Recent advances in detection technologies and genetic engineering ...
    (Date:7/6/2015)... ... July 06, 2015 , ... “ TapGlance ” was featured on NewsWatch ... coolest applications on the market for iOS, Android, and Windows. Joe Toohey, the host ... this interior design app helps users visualize what rooms will look like before they ...
    (Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... Shortly after ... Liens , the leading network of doctors working on a lien basis. Dr. ... on Liens. , The daughter of two Cambodian refugees, Dr. Lim suffered with back ...
    (Date:7/6/2015)... ... 2015 , ... The Asian-Pacific market for rheumatoid arthritis therapeutics reached a value ... a CAGR of over 3.2 percent in the years to come to hit the ... spurred by an anticipated launch of a number of promising pipeline candidates and an ...
    Breaking Medicine News(10 mins):Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 3Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 2Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 3Health News:Create a Space with TapGlance, a Revolutionary Interior Design Application 2Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2
    ... that the antipsychotic drug, clozapine has some very concerning ... available. ,"Clozapine is the last hope for ... study suggests that patients who need the most effective ... said J. Steven Lamberti, the lead author of the ...
    ... Weight loss surgery has more benefits that simply reducing the ... at the McGill University// . ,The researchers ... The study followed these people from 1986 to 2002. All ... compared with 5,700 people who did not undergo such surgery. ...
    ... with a hit in the head with the ball. While ... dizzy and queasy// you often just continue playing. The question ... signs of concussion—one of the least understood sports injuries, says ... of Indianapolis. “People assume a concussion means you’re unconscious but ...
    ... all the popular opinion by saying that beer is ... to all the beer lovers. ,Charles Bamforth, ... of California at Davis and an Anheuser-Busch endowed professor, ... valuable B vitamins, such as B12, folic acid and ...
    ... World Food Programme (WFP) announced on Wednesday that as ... acute food shortage in Southern Africa. //WFP executive director ... recent years, there was a distribution problem. ... to eat," he said. "Food and good nutrition are ...
    ... Degeneration (AMD) is higher among the people who smoke ... ,Current cigarette smoking was associated with a fivefold ... associated with a twofold higher risk of AMD. The ... higher risk of AMD, compared with non-smokers with the ...
    Cached Medicine News:Health News:Beer is More Healthier Than Wine 2Health News:Cigarette Smoking and High Body Mass Index Increase the Risk of AMD 2
    ... Captique is a non-animal stabilized ... newest HA filler to enter the ... correction of moderate to severe facial ... folds). Captique is injected just under ...
    ... Radiesse brings you into the new ... can now offer your patients immediate, long-term ... and flexibility. This injectable filler offers superior ... cosmetic and reconstructive treatments. Long-lasting, Radiesse saves ...
    The HEMOCHRON Model 401 is a portable, single-well whole blood coagulation monitoring instrument. The 401 provides on-screen plasma equivalent PT and APTT test results....
    ... clinically proven to reduce the appearance of ... formula combines Retinol, the purest form of ... It works deep within skin's surface to ... appearance. Fast absorbing, it has a fresh, ...
    Medicine Products: